![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Depomed's Proquin XR for Urinary Tract Infections
FDA Approves Depomed's Proquin XR for Urinary Tract Infections
Depomed has received FDA approval for Proquin XR, a once-daily, extended-release formulation of ciprofloxacin HCl for the treatment of uncomplicated urinary tract infections (UTIs).
The market for ciprofloxacin is estimated at $1.5 billion worldwide in the U.S., with prescriptions for uncomplicated UTI's representing a significant portion of usage, Depomed said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct